Point72 Hong Kong Ltd Acquires New Stake in LivaNova PLC (NASDAQ:LIVN)

Point72 Hong Kong Ltd purchased a new stake in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 15,438 shares of the company's stock, valued at approximately $715,000.

Several other hedge funds have also recently made changes to their positions in LIVN. Vanguard Group Inc. boosted its stake in LivaNova by 12.7% during the fourth quarter. Vanguard Group Inc. now owns 2,349,887 shares of the company's stock worth $108,823,000 after buying an additional 265,291 shares during the period. Capital Research Global Investors increased its holdings in LivaNova by 19.1% during the 4th quarter. Capital Research Global Investors now owns 1,612,818 shares of the company's stock worth $74,690,000 after purchasing an additional 258,730 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of LivaNova by 8.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,310,990 shares of the company's stock worth $60,710,000 after buying an additional 107,693 shares during the period. Nuveen Asset Management LLC grew its holdings in LivaNova by 0.6% during the 4th quarter. Nuveen Asset Management LLC now owns 823,412 shares of the company's stock worth $38,132,000 after acquiring an additional 5,080 shares in the last quarter. Finally, Emerald Advisers LLC boosted its stake in shares of LivaNova by 8.2% during the fourth quarter. Emerald Advisers LLC now owns 752,540 shares of the company's stock valued at $34,850,000 after purchasing an additional 57,035 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have commented on LIVN. Stifel Nicolaus reduced their target price on shares of LivaNova from $72.00 to $60.00 and set a "buy" rating for the company in a report on Wednesday, February 26th. Wolfe Research cut LivaNova from an "outperform" rating to a "peer perform" rating in a research report on Wednesday, February 26th. StockNews.com lowered shares of LivaNova from a "strong-buy" rating to a "buy" rating in a research note on Thursday, May 8th. Barclays lowered their price objective on LivaNova from $56.00 to $55.00 and set an "equal weight" rating on the stock in a research report on Thursday, May 8th. Finally, Robert W. Baird lifted their price target on LivaNova from $55.00 to $61.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $59.17.

LivaNova Stock Down 1.0%

LivaNova stock traded down $0.43 during trading on Monday, reaching $43.97. The stock had a trading volume of 476,361 shares, compared to its average volume of 645,674. The stock has a market cap of $2.40 billion, a PE ratio of 104.69 and a beta of 0.84. The business has a 50 day moving average price of $38.39 and a 200 day moving average price of $44.81. LivaNova PLC has a 52-week low of $32.48 and a 52-week high of $62.04. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.